(Q35906315)

11 August 2017

1 reference

title

Current and future immunosuppressive strategies in renal transplantation (English)

1 reference

11 August 2017

Karen L Hardinger

1

1 reference

11 August 2017

Matthew J Koch

series ordinal

2

1 reference

11 August 2017

Daniel C Brennan

series ordinal

3

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

24

1 reference

11 August 2017

issue

9

1 reference

11 August 2017

page(s)

1159-1176

1 reference

Patient management by Neoral C(2) monitoring: an international consensus statement

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Chronic rejection and graft half-life: five-year follow-up of the European Tacrolimus Multicenter Renal Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Rapamycin: signaling in vascular smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Pharmacokinetics of tacrolimus-based combination therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Sirolimus and lymphocele formation after kidney transplantation: an immunosuppressive medication as co-factor for a surgical problem?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to Cyclosporine-based immunosuppressive regimens in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Differential effects of modern immunosuppressive agents on the development of intimal hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

High level of TGF-beta in organ transplantation might be due to rejection rather than calcineurin inhibitor medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Enteric coating of mycophenolate sodium: a rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

West Nile Virus-Associated Meningoencephalitis in Two Chronically Immunosuppressed Renal Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients1

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Steroid withdrawal in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Antibody-mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Anti-CD40 therapy extends renal allograft survival in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Peripheral expression of Jak3 is required to maintain T lymphocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Review of T-cell activation: impact of Janus kinase 3 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Experiences with leflunomide in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

FTY 720A mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Tolerogenic immunosuppression for organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

IVIG rescue therapy in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Cell migration, chimerism, and graft acceptance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Antigen localization and migration in immunity and tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

A BLINDED, LONG-TERM, RANDOMIZED MULTICENTER STUDY OF MYCOPHENOLATE MOFETIL IN CADAVERIC RENAL TRANSPLANTATION

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.13.1159.38094

10.1592/PHCO.24.13.1159.38094

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference